Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

About this update from Coya Therapeutics, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":213,"url":"https://media.zenfs.com/en/business-wire.com/1adb2a38bd71498830d5e6b8e71d2680"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CcEBVNbZwc7Y0KCwmW.ksw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1adb2a38bd71498830d5e6b8e71d2680","width":480,"height":213}},"lazy":false},{"type":"text","content":"HOUSTON, November 12, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025.","length":376,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Published a study in Frontiers in Immunology linking inflammation and oxidative stress to the progression of Parkinson’s disease.","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced FDA acceptance of Investigational New Drug (IND) application for COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).","length":141,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received $4.2 million from strategic partner Dr. Reddy’s Laboratories for the achievement of IND approval milestone.","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Launched the ALSTARS Trial, a Phase 2 clinical study to assess the efficacy and safety of COYA 302 in ALS.","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced COYA 302 ALS Trial accepted by NEALS as a NEALS-affiliated trial.","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported results from the first cohort of a preclinical in-vivo animal study demonstrating COYA 303 (LD IL-2 and GLP-1RA) showed promising Central Nervous System (CNS) anti-inflammatory effects and systemic regulatory T cell (Treg) enhancing effects.","length":250,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed patient enrollment...

More updates from Coya Therapeutics, Inc.